Ongoing Challenges in the Diagnosis of Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease

Patrick Lipps; Ana Beatriz Ayroza Galvão Ribeiro Gomes; Laila Kulsvehagen; Matthias Anthony Mutke; Jens Kuhle; Athina Papadopoulou; Anne-Katrin Pröbstel

doi:10.1001/jamaneurol.2023.3956

Ongoing Challenges in the Diagnosis of Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease

JAMA Neurol. 2023 Dec 1;80(12):1377-1379. doi: 10.1001/jamaneurol.2023.3956.

Authors

Patrick Lipps^{1

2

3}, Ana Beatriz Ayroza Galvão Ribeiro Gomes^{1

2

3}, Laila Kulsvehagen^{1

2

3}, Matthias Anthony Mutke⁴, Jens Kuhle^{1

2

3}, Athina Papadopoulou^{1

3

5}, Anne-Katrin Pröbstel^{1

2

3}

Affiliations

¹ Department of Neurology, University Hospital of Basel and University of Basel, Basel, Switzerland.
² Departments of Biomedicine and Clinical Research, University Hospital of Basel and University of Basel, Basel, Switzerland.
³ Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), University Hospital of Basel and University of Basel, Basel, Switzerland.
⁴ Clinic of Radiology and Nuclear Medicine, Division of Diagnostic and Interventional Neuroradiology, University Hospital of Basel and University of Basel, Basel, Switzerland.
⁵ Translational Imaging in Neurology (ThINk) Basel, Department of Biomedical Engineering, University Hospital of Basel and University of Basel, Basel, Switzerland.

No abstract available

Plain language summary

This cross-sectional study examines whether proposed myelin oligodendrocyte glycoprotein antibody–associated disease (MOGAD) diagnostic criteria can exclude other diseases, such as multiple sclerosis, and rely on results of cell-based assays.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Aquaporin 4
Autoantibodies*
Humans
Longitudinal Studies
Myelin-Oligodendrocyte Glycoprotein
Neuromyelitis Optica*

Substances

Myelin-Oligodendrocyte Glycoprotein
Autoantibodies
Aquaporin 4